Abstract 5242
Background
Until now, we have managed all CRC patients (pts) in the same way, However, emergent data show that location of primary tumour can have a prognostic and predictive value in metastatic setting. In this study, we analized differences in sv for every stage between right (R) and left-sided (L) CRC.
Methods
This prospective, multicentre observational study was conducted in coordination with 22 public-sector hospitals of Spain. Pts diagnosed with new CRC, stage I-IV and surgically treated, were included. We defined R-CRC as tumours originated in cecum, ascending colon, hepatic flexure or transverse colon, and L in splenic flexure, descending and sigmoid colon or rectum.
Results
Data from 1742 pts were examined for sidedness, stage, and survival at 2 years. 509 (29.2%) had R and 1233 (70.8%) L-CRCs. Most of cases were non-metastatic (92.3%), and males (63.4%). At 2 years, 14.2% of R-CRCs and 15.8% of L-CRCs experienced a recurrence (p 0.408). Nevertheless, the survival analysis revealed a poorer outcome for R-CRCs, with less patients alive at 2 years: 86.6% (CI 95%:83.5 - 89.6) than L-CRCs: 92.4% (CI 95% 90.8 - 93.8); p < 0.001. The prognosis was significantly better for L-tumours in more advanced stages (III and IV), and in stage I as well. Patients with stage II seemed to have a very similar outcome, regardless their tumours were placed in right or left side. Only survival mean was slightly higher in R-CRCs, but percentage of survival at 2 years was the same for two both sides, without showing any statistical difference.Table:
594P Differences in survival between R-CRC and L-CRC in every stage
Stage | n(%) | Sv 2 years, % | p | |
---|---|---|---|---|
R-CRC | L-CRC | |||
I | 374 (21.5) | 92.2 | 97.6 | 0.049 |
II | 641 (36.8) | 93.8 | 93.7 | 1.0 |
III | 594 (34.1) | 83.4 | 91.2 | 0.009 |
IV | 133 (7.6) | 48.6 | 75.5 | 0.006 |
Conclusions
Overall, prognosis is better for L-tumours in every stage, most notably in advances stages (III-IV). However, stage II behaves in a distinct manner and no differences in survival are found between R-CRC and L-CRCs in these pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
REDISSEC.
Funding
REDISSEC (RD12/0001/0010), Fondo de Investigaciones Sanitarias (13/0013) and Fondo Europeo de Desarrollo Regional (FEDER).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3180 - Genomic analysis of hepatobiliary lithiasis associated cholangiocarcinoma revealed a distinct subtype feature.
Presenter: Lunda Gu
Session: Poster Display session 2
Resources:
Abstract
4891 - Comparison of the impact of stereotactic body radiation therapy vs. radiofrequency ablation on liver function in patients with single hepatocellular carcinoma: A propensity score matching analysis
Presenter: Masayuki Ueno
Session: Poster Display session 2
Resources:
Abstract
3203 - Exploratory analysis based on tumor location and early metabolic tumor response of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine/platinum-based chemotherapy for advanced and metastatic biliary tract tumors.
Presenter: Anne Demols
Session: Poster Display session 2
Resources:
Abstract
1602 - Predictive Value of Neutrophil-Lymphocyte Ratio (NLR) And Platelet-Lymphocyte Ratio (PLR) In Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab (N)
Presenter: Sirish Dharmapuri
Session: Poster Display session 2
Resources:
Abstract
2848 - Preliminary Safety and Pharmacokinetics of a New Lysosomotropic Oral Agent, GNS561, in a First-in-Human Study in Advanced Primary Liver Cancer Patients
Presenter: Ahmad Awada
Session: Poster Display session 2
Resources:
Abstract
1396 - A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results
Presenter: Josep Llovet
Session: Poster Display session 2
Resources:
Abstract
1139 - Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study
Presenter: Andrea Casadei-gardini
Session: Poster Display session 2
Resources:
Abstract
4688 - Prognostic and predictive factors from the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Tim Meyer
Session: Poster Display session 2
Resources:
Abstract
1492 - A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL.
Presenter: David Pinato
Session: Poster Display session 2
Resources:
Abstract
3159 - Anlotinib for advanced hepatocellular carcinoma: interim results from the phase II ALTER0802 study
Presenter: AiPing Zhou
Session: Poster Display session 2
Resources:
Abstract